Scriptlinkrx
SolutionsPharmaciesBlog
Log inGet started

ScriptLinkRx Resources

Compounding Guides for Providers

Provider guides to compounded medications and regulatory updates for clinics ordering from 503A compounding pharmacies and 503B outsourcing facilities.

Browse by category

Guides for Clinics2Regulatory Updates3GLP-1 & Metabolic7Peptides Under FDA Review2Longevity & Wellness2Hormone & Growth1Sexual Wellness2Skin & Aesthetics1

Ordering for your clinic?

See how clinics order compounded medications from licensed pharmacies.

Request a Demo

Guides for Clinics

Practical guides to choosing and running a compounded-medication program

Clinic Guide

503A vs 503B Compounding: What Clinics Need to Know Before Ordering

503A pharmacies fill prescriptions for named patients; 503B outsourcing facilities supply office stock. How the two differ and which one a clinic needs.

November 11, 2026·7 min read→
Clinic Guide

How to Choose a Compounding Pharmacy Ordering Platform: A 2026 Guide for Clinics

A neutral checklist for clinics comparing compounding pharmacy ordering platforms: licensing, 503A/503B access, pricing, compliance and red flags.

October 14, 2026·8 min read→

Regulatory Updates

FDA, PCAC and state developments that change how clinics source compounded medications

Regulatory Update

FDA's Proposal to Exclude Semaglutide, Tirzepatide and Liraglutide From the 503B Bulks List

On April 30, 2026 the FDA proposed removing semaglutide, tirzepatide and liraglutide from the 503B bulks list. What it means for office-use ordering.

Updated November 13, 2026·3 min read→
Regulatory Update

FDA's September 2026 Warning Letter to Empower: What It Means for Clinics Ordering Compounded GLP-1s

The FDA's September 18, 2026 warning letter called semaglutide-B12 and tirzepatide-niacinamide compounds essentially copies. What clinics should change.

Updated November 13, 2026·4 min read→
Regulatory Update

PCAC's July 2026 Peptide Votes: BPC-157, TB-500 and What Happens Next

The FDA's PCAC voted to recommend BPC-157, TB-500, KPV, MOTS-c, Semax and Epitalon for the 503A bulks list. What the votes mean and what to watch.

Updated November 13, 2026·4 min read→

GLP-1 & Metabolic

Incretin-based formulations for weight-management and metabolic programs

Fact Check

Compounded Semaglutide with Cyanocobalamin (B12): What Providers Should Know

Compounded semaglutide with B12: regulatory status after the shortage resolution, additive justification, and pharmacy vetting questions for providers.

Updated November 13, 2026·8 min read→
Fact Check

Compounded Semaglutide with Pyridoxine (B6): A Provider's Guide

What clinics should know about compounded semaglutide with pyridoxine (B6): regulatory status after the 2025 shortage resolution, sourcing, and quality.

Updated November 13, 2026·10 min read→
Fact Check

Compounded Tirzepatide with Cyanocobalamin (B12): What Providers Should Know

Regulatory status, additive justification, and sourcing questions for compounded tirzepatide with B12 — a provider-focused guide, updated November 2026.

Updated November 13, 2026·9 min read→
Fact Check

Compounded Tirzepatide with L-Carnitine: A Provider's Overview

A provider guide to compounded tirzepatide with L-carnitine: regulatory status, FDA combination scrutiny, and sourcing questions for clinics.

Updated November 13, 2026·8 min read→
Fact Check

Compounded Tirzepatide with NAD+ and L-Carnitine: Provider Considerations

A regulatory overview of compounded tirzepatide with NAD+ and L-carnitine for providers: the essentially-a-copy framework and two-additive scrutiny.

Updated November 13, 2026·8 min read→
Fact Check

Compounded Tirzepatide with Pyridoxine (B6): A Provider's Guide

A provider guide to compounded tirzepatide with pyridoxine (B6): essentially-a-copy limits, the 2026 503B bulks proposal, and pharmacy quality questions.

Updated November 13, 2026·10 min read→
Fact Check

Retatrutide: Regulatory Status and What Providers Need to Know

Retatrutide is not FDA-approved and cannot legally be compounded as of November 2026. A regulatory fact check for clinics fielding patient questions.

Updated November 13, 2026·7 min read→

Peptides Under FDA Review

Peptides under active FDA and PCAC review in 2026

Fact Check

BPC-157: Compounding and Regulatory Status for Providers

A regulatory-literate overview of BPC-157's FDA compounding status in 2026, including the April 2026 Category 2 removal and the July 23–24, 2026 PCAC vote.

Updated November 13, 2026·8 min read→
Fact Check

TB-500 (Thymosin Beta-4 Fragment): Provider Overview and Regulatory Status

TB-500, a thymosin beta-4 fragment: a provider overview of its class, compounding forms, limited human evidence, and 2026 FDA regulatory status.

Updated November 13, 2026·8 min read→

Longevity & Wellness

Compounds ordered by longevity and wellness practices

InjectionCapsuleNasal Spray

Compounded Glutathione: Forms and Provider Considerations

A provider guide to compounded glutathione: forms, sterile-compounding standards, the endotoxin contamination history, and pharmacy sourcing questions.

Updated November 13, 2026·8 min read→
InjectionNasal Spray

Compounded NAD+ for Clinics: Forms, Practice Context, and Sourcing

A provider guide to compounded NAD+: what it is, how longevity and wellness clinics use it, its forms, and sterile-compounding questions to ask a pharmacy.

Updated November 13, 2026·8 min read→

Hormone & Growth

GH-axis and hormone-adjacent formulations

InjectionCapsuleTrocheNasal Spray

Compounded Sermorelin: A Provider's Guide

A provider-focused guide to compounded sermorelin acetate: its GHRH mechanism, clinical use context, and 2026 regulatory and sourcing considerations.

Updated November 13, 2026·7 min read→

Sexual Wellness

Sexual-health formulations and their regulatory context

InjectionNasal SprayCapsule

Bremelanotide (PT-141): Compounded Forms and Provider Considerations

A regulatory-literate overview of compounded PT-141 (bremelanotide) for clinics: mechanism, forms, essentially-a-copy analysis, and sourcing due diligence.

Updated November 13, 2026·6 min read→
InjectionNasal SprayTrocheTablet

Compounded Oxytocin: What Providers Should Know

A regulatory guide to compounded oxytocin for clinics: nasal spray and troche forms, off-label context, FDA status, and pharmacy sourcing questions.

Updated November 13, 2026·7 min read→

Skin & Aesthetics

Topical and aesthetic formulations for dermatology and med spas

Fact Check

GHK-Cu (Copper Peptide): Topical and Injectable Forms for Clinics

How compounding pharmacies prepare GHK-Cu copper peptide in topical and injectable forms, the cosmetic-versus-drug line, and its 2026 FDA status.

Updated November 13, 2026·7 min read→
LegitScript Certified

A 503A and 503B compounding pharmacy network for clinics, med spas and telehealth practices—one platform for ordering, e-prescribing and tracking.

Categories

  • Weight Management
  • Sexual Health
  • Hormone Therapy
  • Hair & Skin
  • General Health & Wellness

Solutions

  • 503A pharmacy ordering
  • 503B office-use ordering
  • TRT sourcing
  • Peptide sourcing
  • GLP-1 sourcing
  • For med spas
  • For telehealth companies

Main

  • Homepage
  • Request a demo
  • View Catalog
  • Partner pharmacies
  • Coverage by state
  • Blog

 

  • About
  • Privacy Policy
  • Terms and Services

© 2026 ScriptLinkRx. All rights reserved.

Back to top
Scriptlinkrx